However, compared with the highly effective CFTR modulator therapy with ivacaftor in patients with CF and a Gly551Asp gating mutation or with the recently approved new combination therapy composed of the correctors elexacaftor and tezacaftor and the potentiator ivacaftor, LUM/IVA therapy only showed a moderate effect on lung function with high heterogeneity between patients [29,30,31,32,33]. The gene discussed is CFTR; the disease is cystic fibrosis.